Preclinical drug discovery for new anti-pneumocystis compounds

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Pneumocystis pneumonia (PCP) is a significant cause of fatal pneumonia in HIV/AIDS patients and other immunocompromised individuals.
• Preclinical drug discovery for anti-PCP agents has been significantly challenged by the absence of a continuous in vitro growth system.
• Trimethoprim-sulfamethoxazole has been the primary prophylactic and therapeutic agent for PCP since 1978.

Purpose of the Study:

• To review current in vitro and in vivo systems used for screening anti-PCP drug candidates.
• To discuss strategies and successes in identifying novel agents against Pneumocystis.
• To highlight future prospects for PCP drug discovery, including potential new genomic targets.

Main Methods:

• Review of short-term in vitro assays, including cell monolayer-based and cell-free systems.
• Inclusion of in vivo studies using rodent models of Pneumocystis infection.
• Analysis of drug screening strategies, including testing existing clinical agents and their derivatives.

Main Results:

• Current methods primarily involve screening compounds like dapsone, atovaquone, and pentamidine analogues.
• Successful identification of primaquine-clindamycin for moderate PCP and beta-glucan synthase inhibitors shows promise.
• Despite challenges, progress in identifying novel agents has been achieved using existing experimental systems.

Conclusions:

• Existing in vitro and in vivo models, while limited, have facilitated progress in PCP drug discovery.
• Further advancements are anticipated with the ongoing annotation of the Pneumocystis genome, potentially revealing new therapeutic targets.
• Continued research into novel agents and drug discovery systems is essential for combating fatal PCP cases.